Friday, July 21, 2017 News Recap 1) Vosevi Approved in US – Under Review in Canada Vosevi has just been approved in the USA to treat adults with chronic HCV genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing sofosbuvir, velpatasvir and a new drug, voxilaprevir. Vosevi is the first treatment approved for patients who have been previously treated with DAAs and failed treatment....
The complications include liver cancer, failure, transplantation or death. Consistent medical monitoring is recommended. Individuals who are treated for hepatitis C virus (HCV) when they have advanced fibrosis or cirrhosis remain at high risk of liver disease progression even after being cured of the virus. Consequently, researchers recommend routine monitoring for this group. Publishing their findings in the Journal of Hepatology, researchers conducte
Study by Baylor College of Medicine has tracked how jet lag affects the liver. They found it creates bile acid buildup akin to that seen in obese people. Experts warn this drives up cancer risk for frequent fliers and shift workers. Frequent fliers have the same cancer risk as obese people, according to a new study. Jet lag drastically raises one's risk of liver cancer by driving up bile acid levels in the liver, creating buildup akin to that seen in o
It’s no secret that excessive alcohol consumption is dangerous to the liver; that’s exactly why patients with hepatitis C are advised to steer clear of it. But more precise outcomes in this population who do partake in light-to-moderate drinking hasn’t been fully understood. A collaborative team of researchers from Belgium and Switzerland set out to find how alcohol intake and viral eradication impacted the risk of hepatocellular carcinoma (HCC), decompen